Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Novel production of baker´s yeast strains, Saccharomyces cerevisiae, optimised for industrial-scale recombinant protein production

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20201201002
Publicado:
29/01/2021
Caducidad:
30/01/2022
Resumen:
A UK biofoundry SME provides novel production strains of the regulatory friendly baker´s yeast, optimised for industrial-scale recombinant protein production to make vaccines, therapeutic proteins and diagnostics more affordable and accessible to all who need them. Biotech partners are sought for technology platform development and testing under technical cooperation agreements, and customers with products suited to their technology platform under commercial agreements with technical assistance.

Details

Tittle:
Novel production of baker´s yeast strains, Saccharomyces cerevisiae, optimised for industrial-scale recombinant protein production
Summary:
A UK biofoundry SME provides novel production strains of the regulatory friendly baker´s yeast, optimised for industrial-scale recombinant protein production to make vaccines, therapeutic proteins and diagnostics more affordable and accessible to all who need them. Biotech partners are sought for technology platform development and testing under technical cooperation agreements, and customers with products suited to their technology platform under commercial agreements with technical assistance.
Description:
A biofoundry SME based in the Midlands region of the UK create and own yeast synthetic biology solutions to make any recombinant protein. Their mission is to provide novel production strains of the regulatory friendly baker´s yeast, Saccharomyces cerevisiae (S. cerevisiae) optimised for industrial-scale recombinant protein production, e.g. to make vaccines, therapeutic proteins and diagnostics more affordable and accessible to all of those who need them.

S. cerevisiae is already well-established for large-scale Current Good Manufacturing Practice (cGMP) manufacturing of Food and Drug Administration (FDA) approved biologics, and the company has a collection of around one billion yeast strains specially modified for industrial recombinant protein production.

By starting with their library of yeast strains, they can quickly identify how well they can make a specific protein, and then optimise selected candidates to get the performance characteristics and quality attributes required.

Using proprietary methods developed from modern genomics and synthetic biology, they can select and analyse candidate strains in weeks, not years.

Genome analysis, performed using their QTL (quantitative trait loci) software, can be used to identify the beneficial genetic traits responsible for the improved performance of unique strains and generate valuable IP specifically for particular products.

The company creates proprietary synthetic biology solutions for their customer´s specific proteins in contrast to off-the-shelf expression strains typically tested. They are looking for partners with products for the vaccine, diagnostic and therapeutic protein markets for technology platform development and testing under technical cooperation agreements, and customers with products suited to their technology platform under commercial agreement with technical assistance. Other cooperation types may be considered if requested.
Advantages and Innovations:
The combination of team knowledge and expertise with world-leading yeast technology enables the company to rapidly produce cost-effective production strains optimised for the manufacture of specific proteins under defined bioprocessing conditions. This is achieved by harnessing the natural diversity of their billion different yeast strains to identify those strains with the preferred performance characteristics. They then breed and engineer those strains to exact process requirements.

S. cerevisiae is relatively inexpensive compared to other eukaryotic expression systems, such as mammalian cells, which can correctly fold complex therapeutic products. It grows quickly in low-cost media and both strain development and scale-up pathways are proven and established, with overall production costs being much lower.
Stage of Development:
Project already started
IPs:
Trade Marks
CommeR Statunts Regarding IPR Status:
The company name logo has been trademarked and they are in the process of trademarking their services offerings.

Partners/customers can license strains exclusively for their own use, or the company can identify IP specific to their own processes.

Partner sought

Type and Role of Partner Sought:
Two types of collaboration sought:

1) Company or academic biotechnology partners operating in the the vaccine, diagnostic and therapeutic protein markets for technology platform development, e.g. for optimising or automating unit operations and strain development workflows, high throughput expression, fermentation and screening for beneficial phenotypes (such as high product yield, protease reduction and control of post-translational modifications), and other groups operating in biotechnology process development. Technical cooperation agreements are envisaged.

2) Potential customers (including beta testing customer/partners) with products suited to the company´s technology platform. Commercial agreements with technical assistance are expected but other types of cooperation may be considered on a case by case basis.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
Dutch
English
French
Italian

Keywords

Technology Keywords:
06002006 Biología sintética
06002004 Ingeniería de proteínas
06001015 Productos farmacéuticos / medicamentos
06001006 Vacunas humanas